Progenics Pharmaceuticals (PGNX) Shares Slide -2.66%

Progenics Pharmaceuticals (PGNX) has risen sharply, recording gains of 32.05% in the past 4 weeks. However, the stock has corrected -2.66% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 27.76% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The stock has recorded a 20-day Moving Average of 9.27% and the 50-Day Moving Average is 17.66%. Progenics Pharmaceuticals, Inc. is up 10.17% in the last 3-month period. Year-to-Date the stock performance stands at -4.57%.


Progenics Pharmaceuticals (NASDAQ:PGNX): stock turned positive on Friday. Though the stock opened at $5.8, the bulls momentum made the stock top out at $5.937 level for the day. The stock recorded a low of $5.78 and closed the trading day at $5.85, in the green by 0.69%. The total traded volume for the day was 1,243,128. The stock had closed at $5.81 in the previous days trading.

Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.